Publication Name	World Journal of Gastrointestinal Pathophysiology
Manuscript ID	9447
Country	Greece

Received	2014-02-12 23:57
Peer-Review Started	2014-02-13 09:58
To Make the First Decision	2014-02-27 09:34
Return for Revision	2014-03-11 21:25
Revised	2014-04-15 00:22
Second Decision	2014-07-17 14:18
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-07-17 14:35
Articles in Press	2014-07-17 14:51
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-10-29 17:22
Publish the Manuscript Online	2014-11-19 10:25

ISSN	2150-5330 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Treatment of Helicobacter pylori infection: Past, present and future
Manuscript Source	Invited Manuscript
All Author List	Vasilios Papastergiou, Sotirios D Georgopoulos and Stylianos Karatapanis
Funding Agency and Grant Number
Corresponding Author	Stylianos Karatapanis, MD, PhD, Department of Internal Medicine, General Hospital of Rhodes, 10 Kalopetras Str, 85100 Rhodes, Greece. stylkar@otenet.gr
Key Words	Helicobacter pylori; Antibiotic resistance; Bismuth-quadruple; Concomitant; Sequential; Probiotics
Core Tip	Worldwide increase in prevalence of macrolide resistance has accounted for the failure of standard therapies for the treatment of Helicobacter pylori (H. pylori) infection. Bismuth quadruple, concomitant, sequential and hybrid therapies are now recommended as first-line empirical treatments providing improved efficacy in high clarithromycin resistance settings. As quinolone resistance is rapidly increasing, levofloxacin should be preferentially used in second-line/rescue therapies. There is increasing evidence that adjunct probiotic supplementation improves the therapeutic outcome and tolerability. Genotypic characterization of H. pylori susceptibility to therapy may allow for a tailored therapeutic approach in the future.
Publish Date	2014-11-19 10:25
Citation	Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: Past, present and future. World J Gastrointest Pathophysiol 2014; 5(4): 392-399
URL	http://www.wjgnet.com/2150-5330/full/v5/i4/392.htm
DOI	http://dx.doi.org/10.4291/wjgp.v5.i4.392

Full Article (PDF)	WJGP-5-392.pdf
Full Article (Word)	WJGP-5-392.doc
Manuscript File	9447-Review.docx
Answering Reviewers	9447-Answering reviewers.pdf
Copyright License Agreement	9447-Copyright assignment.pdf
Peer-review Report	9447-Peer review(s).pdf
Scientific Misconduct Check	9447-CrossCheck.jpg
Scientific Editor Work List	9447-Scientific editor work list.pdf